nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Use of these materials in therapeutic and diagnostic contexts are also a part of the invention.

IN THE CLAIMS

Please cancel claims 22-36 without prejudice. Add claims 37-50 which follow. Please charge any necessary fees to Deposit Account 500624.

Claim 37: An isolated nucleic acid molecule which encodes a tumor rejection antigen precursor, wherein the complementary sequence of said isolated nucleic acid molecule hybridizes to the nucleotide sequence set forth in SEQ ID NO: 18 at 0.1XSSC, 0.1%SDS.

Claim 38: An isolated nucleic acid molecule which encodes a fragment of a tumor rejection antigen precursor, wherein the complementary sequence of said isolated nucleic acid molecule hybridizes to the nucleotide sequence set forth in SEQ ID NO: 18 at 0.1XSSC, 0.1%SDS.

Claim 39: An isolated nucleic acid molecule which encodes a tumor rejection antigen, wherein the complementary sequence of said isolated nucleic acid molecule hybridizes to the nucleotide sequence set forth in SEQ ID NO: 18 at 0.1XSSC, 0.1%SDS.

Claim 40: The isolated nucleic acid molecule of claim 37, wherein said nucleic acid molecule is cDNA.

Claim 41: An isolated cDNA molecule which encodes a fragment of a tumor rejection antigen precursor, wherein said fragment is processed by cell to a tumor rejection antigen, wherein the complementary sequence of said isolated nucleic acid molecule hybridizes to nucleotides 451-1156 of SEQ ID NO: 18 at 0.1XSSC, 0.1%SDS.

Claim 42: The isolated nucleic acid molecule of claim 37, comprising SEQ ID NO: 18.

Claim 43: An expression vector comprising the isolated nucleic acid molecule of claim 40, operably linked to a promoter.

Claim 44: An expression vector comprising the isolated nucleic acid molecule of claim 41, operably linked to a promoter.